Q-omics provides the consensus-scored GUSBP17 profile across patient tissues and cancer cell-line models. GUSBP17 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GUSBP17 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, GUSBP17 RNA expression shows 4,916 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight UCEC, COAD, and BRCA as cancer lineages where GUSBP17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSBP17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSBP17 survival associations across molecular data types. GUSBP17 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSBP17 RNA expression–survival associations across cancer types. High GUSBP17 expression shows unfavorable associations in UCEC, UVM, CHOL, LAML and THCA, but favorable associations in OV. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for GUSBP17 RNA expression.
This table summarizes GUSBP17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GUSBP17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSBP17 shows lower tumor expression in COAD and KICH. The COAD box plot shows higher GUSBP17 RNA expression in normal versus tumor tissue (log2 FC = −0.024, t-test p = .022).
This table shows molecular features associated with GUSBP17 in patient tissues and cancer cell lines. In patient samples, GUSBP17 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
